InsidersTradesSigma
Track the GENFIT stock price and the full directors' dealings record of the company, a publicly traded company based in France. Shares trade on the FR market, under the supervision of AMF. Operating in the Healthcare & Pharma sector, GENFIT has logged 9 reports. Market capitalisation: €516m. The latest transaction was reported on 4 March 2026 (Exercice). Among the most active insiders: Pascal Prigent. The full history is accessible without an account.
9
Insider Decl.
n/a
Thresholds
€181,391
6 ops.
Buy Volume
n/a
n/a
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate GENFIT Strong Buy (bullish), based on 4 analysts. Average price target: €14.00.
57Σ signal
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 4 March 2026
Declarations9 total
28,958 shares@ €3.08050.020% mcap100.0% of flowOption d'achatEuronext ParisISIN FR00041631112026DD1098600
5,300 shares@ €3.67750.9% of flowActionEuronext ParisISIN FR00041631112023DD918885
Canonical exit: 5 Oct 2023 (T+90)
10,000 shares@ €3.706151.5% of flowActionEuronext ParisISIN FR00041631112023DD918358
Canonical exit: 3 Oct 2023 (T+90)
10,000 shares@ €3.69651.9% of flowActionEuronext ParisISIN FR00041631112023DD918364
Canonical exit: 4 Oct 2023 (T+90)
5,300 shares@ €3.541549.1% of flowActionEuronext ParisISIN FR00041631112023DD917873
Canonical exit: 1 Oct 2023 (T+90)
4 shares0ActionEuronext ParisISIN FR00041631112022DD864906
2,000 shares0ActionEuronext ParisISIN FR00041631112022DD864869
10,000 shares@ €3.4248.1% of flowActionEuronext ParisISIN FR00041631112022DD824658
Canonical exit: 31 May 2022 (T+90)
10,000 shares@ €3.491248.5% of flowActionEuronext ParisISIN FR00041631112022DD824665
Canonical exit: 1 Jun 2022 (T+90)
9 of 9 declarations
关于 GENFIT
GENFIT是一家法国生物制药公司，在Euronext Paris交易所上市，股票代码为GNFT，ISIN代码为FR0004163111。公司成立于1999年，由现任董事会主席Jean-François Mouney在法国创办，长期以来在肝脏疾病领域建立了专业能力，特别关注具有重大未满足医疗需求的罕见和严重疾病。公司总部位于法国Loos（靠近Lille），集团还在美国马萨诸塞州Cambridge和瑞士Zurich设有运营机构。随着时间推移，GENFIT已从以研究为主的组织演变为拥有多元化研发组合的后期生物制药公司。历史上，公司还通过与主要制药企业的战略合作和许可协议展示了创造价值的能力，反映了其推进项目和变现资产的良好记录。 GENFIT的核心业务现已聚焦于罕见和危及生命的肝脏疾病，战略重点是急性-慢性肝衰竭（ACLF）。其ACLF产品线包括多个在研资产，基于互补的作用机制和不同的给药途径。同时，公司还在胆管癌、尿素循环障碍和某些有机酸血症等严重适应症领域推进其他项目。GENFIT还开发非侵入性诊断解决方案，特别是针对MASH/NASH和氨相关疾病检测的技术，强化了其在肝脏疾病管理全程护理中的价值主张。集团已证明其能够将药物候选物从早期发现推进至后期临床开发和商业化前阶段，这一点通过elafibranor在原发性胆汁性胆管炎中的第3期ELATIVE研究的成功得到突出体现。 从市场和财务角度看，GENFIT定位为具有强大科学信誉和高价值医疗及经济机遇敞口的专业细分领域参与者。公司最近加强了国际足迹和财务灵活性，特别是通过非稀释性融资安排和与合作伙伴相关的收入。其跨大西洋地理位置使其能够结合欧洲科学能力与美国市场和关键生物技术生态系统的准入。因此，GENFIT仍是一只增长型医疗保健股票，其表现与临床执行、监管里程碑和治疗及诊断管线的变现密切相关。
